int8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of
Report (date of earliest event reported)
MICROFLUIDICS
INTERNATIONAL CORPORATION
(Exact
name of registrant as specified in its charter)
|
Commission
file number
0-11625
|
DELAWARE
|
04-2793022
|
(State
or Other Jurisdiction of Incorporation or Organization)
|
|
|
|
|
|
30
Ossippe Road, Newton, MA
|
02464
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(617)
969-5452
(Registrant's
Telephone No., including Area Code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section
1 – Registrant’s Business and Operations
Item
1.01. Entry into a Material Definitive Agreement.
On May 4, 2009, Microfluidics
International Corporation, a Delaware corporation (the “Company”), and Global
Strategic Partners, LLC (the “Investor”) entered into
Amendment No. 2 (the “Amendment”) to that certain
Debenture and Warrant Purchase Agreement dated as of November 14, 2008 (the
“Debenture”). Pursuant
to the Amendment, the Company and Investor agreed to defer the interest payments
due and payable on each of July 1, 2009, October 1, 2009 and January 4, 2010
(the “Deferred
Payments”). The Deferred Payments will accrue interest at nine
percent per annum and will be payable in eight equal quarterly installments on
the first day of such quarter beginning on April 1, 2010.
There were no other material amendments
to the Debenture.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
MICROFLUIDICS
INTERNATIONAL CORPORATION
(Registrant)
May 14,
2009
By: /s/ Peter
Byczko
Peter Byczko
Vice
President of Finance, Chief Accounting Officer